Earnings ·
Aytu BioPharma reports Q4 net revenue of $16.1 million, driven by EXXUA launch generating $3.9 million
AYTUAytu Biopharma, Inc
Aytu BioPharma reported fiscal 2026 fourth quarter net revenue of $16.1 million, a 6.4% increase from the prior year period, driven by the commercial launch of EXXUA which generated $3.9 million in revenue and 3,323 prescriptions. The company achieved an Adjusted EBITDA of $0.5 million for the quarter, while net loss was approximately break-even at less than ($0.1) million due to a $1.0 million derivative warrant liabilities gain. Full-year fiscal 2026 net revenue decreased 13.3% to $57.6 million as the company shifted commercial focus from its ADHD and Pediatric portfolios to EXXUA, resulting in full-year Adjusted EBITDA of ($3.7) million. The company held $26.3 million in cash at June 30, 2026. Aytu BioPharma is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases.